FDA Approved Products
6,646 products with lifecycle intelligence, competitive pressure scores, and patent timelines.
ATRALIN
tretinoin
LOE Approaching
TOPICAL · GEL
2007
NDA30/100
ATRIDOX
doxycycline hyclate
LOE Approaching
PERIODONTAL · SYSTEM, EXTENDED RELEASE
the following infections: Rocky Mountain spotted fevertyphus fever+11
1998
NDA30/100
ATROMID-S
clofibrate
LOE Approaching
Thayer Medical
ORAL · CAPSULE
1967
NDA30/100
ATROPEN
atropine
LOE Approaching
Medcaptain Medical Technology
INTRAMUSCULAR · SOLUTION
poisoning by susceptible organophosphorus nerve agents having cholinesterase activitycarbamate insecticides in adult
1973
NDA30/100
ATROPINE (AUTOINJECTOR)
atropine injection, 2 mg
Peak
INTRAMUSCULAR · SOLUTION
poisoning by susceptible organophosphorus nerve agents having anticholinesterase activitycarbamate insecticides in adults
2018
NDA30/100
ATROPINE SULFATE
atropine sulfate
Peak
Accord Biopharma
INTRAVENOUS · SOLUTION
older for: Atropine is an anticholinergic agent indicated in adultsolder for: Cycloplegia () Mydriasis () Penalization of the healthy eye in the treatment of amblyopia () 1
2020
NDA30/100
ATROPINE SULFATE
atropine sulfate
LOE Approaching
Medica Corp
INHALATION · AEROSOL, METERED
older for: Atropine is an anticholinergic agent indicated in adultsolder for: Cycloplegia () Mydriasis () Penalization of the healthy eye in the treatment of amblyopia () 1
1990
NDA30/100
ATROPINE SULFATE
atropine sulfate
Peak
Fresenius Kabi
INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL · SOLUTION
2018
NDA30/100
ATROPINE SULFATE
atropine sulfate
Peak
Bausch + Lomb
OPHTHALMIC · SOLUTION/DROPS
2022
NDA30/100
ATROPINE SULFATE
atropine sulfate
Peak
OPHTHALMIC · SOLUTION/DROPS
older for: Atropine is an anticholinergic agent indicated in adultsolder for: Cycloplegia () Mydriasis () Penalization of the healthy eye in the treatment of amblyopia () 1
2014
NDA30/100
ATROPINE SULFATE
atropine sulfate
LOE Approaching
Pfizer
INTRAVENOUS · SOLUTION
2001
NDA30/100
ATROVENT
ipratropium bromide
LOE Approaching
Boehringer Ingelheim
NASAL · SPRAY, METERED
COPDchronic obstructive pulmonary disease
1995
NDA30/100
ATROVENT
ipratropium bromide
LOE Approaching
Boehringer Ingelheim
NASAL · SPRAY, METERED
COPDchronic obstructive pulmonary disease
1995
NDA30/100
ATROVENT
ipratropium bromide
LOE Approaching
Boehringer Ingelheim
INHALATION · SOLUTION
COPDchronic obstructive pulmonary disease
1993
NDA30/100
ATROVENT
ipratropium bromide
LOE Approaching
Boehringer Ingelheim
INHALATION · AEROSOL, METERED
COPDchronic obstructive pulmonary disease
1986
NDA30/100
AUGMENTIN '125'
amoxicillin and clavulanate potassium
LOE Approaching
Pfizer
ORAL · FOR SUSPENSION
the following infections in adultsskin structure infections Urinary tract infections Limitations of Use+12
1984
NDA30/100
AUGMENTIN '125'
amoxicillin; clavulanate potassium
LOE Approaching
Pfizer
ORAL · TABLET, CHEWABLE
infections due to susceptible strains of designated microorganismsthe treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus species+4
1985
NDA30/100
AUGMENTIN '200'
amoxicillin; clavulanate potassium
LOE Approaching
Pfizer
ORAL · FOR SUSPENSION
infections due to susceptible strains of designated microorganismsthe treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus species+4
1996
NDA30/100
AUGMENTIN '200'
amoxicillin; clavulanate potassium
LOE Approaching
Pfizer
ORAL · TABLET, CHEWABLE
infections due to susceptible strains of designated microorganismsthe treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus species+4
1996
NDA30/100
AUGMENTIN '250'
amoxicillin; clavulanate potassium
LOE Approaching
Pfizer
ORAL · TABLET
infections due to susceptible strains of designated microorganismsthe treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus species+4
1984
NDA30/100
AUGMENTIN '250'
amoxicillin; clavulanate potassium
LOE Approaching
Pfizer
ORAL · TABLET, CHEWABLE
1985
NDA30/100
AUGMENTIN '250'
amoxicillin and clavulanate potassium
LOE Approaching
Pfizer
ORAL · FOR SUSPENSION
the following infections in adultsskin structure infections Urinary tract infections Limitations of Use+12
1984
NDA30/100
AUGMENTIN '400'
amoxicillin; clavulanate potassium
LOE Approaching
Pfizer
ORAL · FOR SUSPENSION
infections due to susceptible strains of designated microorganismsthe treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus species+4
1996
NDA30/100
AUGMENTIN '400'
amoxicillin; clavulanate potassium
LOE Approaching
Pfizer
ORAL · TABLET, CHEWABLE
infections due to susceptible strains of designated microorganismsthe treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus species+4
1996
NDA30/100